Copie-Bergman C Cuillière-Dartigues P Baia M Briere J Delarue R Canioni D Salles G Parrens M Belhadj K Fabiani B Recher C Petrella T Ketterer N Peyrade F Haioun C Nagel I Siebert R Jardin F Leroy K Jais JP Tilly H Molina TJ Gaulard P 2015 Diffuse large B-cell lymphoma (DLBCL) with MYC rearrangement (MYC-R) carries an unfavorable outcome. We explored the prognostic value of the MYC translocation partner gene in a series of MYC-R de novo DLBCL patients enrolled in first-line prospective clinical trials (Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association) and treated with rituximab-anthracycline-based chemotherapy. A total of 774 DLBCL cases characterized for cell of origin by the Hans classifier were analyzed using fluorescence in situ hybridization with BCL2, BCL6, MYC, immunoglobulin (IG)K, and IGL break-apart and IGH/MYC, IGK/MYC, and IGL/MYC fusion probes. MYC-R was observed in 51/574 (8.9%) evaluable DLBCL cases. MYC-R cases were predominantly of the germinal center B-cell-like subtype 37/51 (74%) with no distinctive morphologic and phenotypic features. Nineteen cases were MYC single-hit and 32 cases were MYC double-hit (MYC plus BCL2 and/or BCL6) DLBCL. MYC translocation partner was an IG gene in 24 cases (MYC-IG) and a non-IG gene (MYC-non-IG) in 26 of 50 evaluable cases. Noteworthy, MYC-IG patients had shorter overall survival (OS) (P = .0002) compared with MYC-negative patients, whereas no survival difference was observed between MYC-non-IG and MYC-negative patients. In multivariate analyses, MYC-IG predicted poor progression-free survival (P = .0051) and OS (P = .0006) independently from the International Prognostic Index and the Hans classifier. In conclusion, we show in this prospective randomized trial that the adverse prognostic impact of MYC-R is correlated to the MYC-IG translocation partner gene in DLBCL patients treated with immunochemotherapy. These results may have an important impact on the clinical management of DLBCL patients with MYC-R who should be routinely characterized according to MYC partner gene. These trials are individually registered at www.clinicaltrials.gov as #NCT00144807, #NCT01087424, #NCT00169143, #NCT00144755, #NCT00140660, #NCT00140595, and #NCT00135499. application/pdf https://sonar.ch/global/documents/77975 eng info:eu-repo/semantics/altIdentifier/doi/10.1182/blood-2015-05-647602 info:eu-repo/semantics/altIdentifier/pmid/26373676 info:eu-repo/semantics/openAccess Blood. - 2015 Adolescent Adult Aged Aged, 80 and over Antibodies, Monoclonal, Murine-Derived Antineoplastic Combined Chemotherapy Protocols Cyclophosphamide Disease-Free Survival Doxorubicin Female Gene Rearrangement Humans Immunoglobulins Lymphoma, Large B-Cell, Diffuse Male Middle Aged Prednisone Proto-Oncogene Proteins c-myc Rituximab Survival Rate Translocation, Genetic Vincristine MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. http://purl.org/coar/resource_type/c_6501